BPIQ Blog

The first week of April didn't have too many major events, although $IFRX did move +183% on Emergency Use Authorization. Looking forward,...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

What Are We Looking At: There are six PDUFA dates in April 2023 for small to large cap biotech. However, a majority of these upcoming...

Summary: We previously analyzed the 36 life science hedge funds to determine which smid-cap biopharmas were in the most Top 20s See our...

We've reached the end of Q1. April has a lot of events happening including 8 PDUFA's, the AACR cancer meeting, and some other company...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Last updated 4/10/23 Summary: AACR is only a few weeks away - the conferences starts April 14th, also when abstract text is released What...

Amgen v. Sanofi Sup Ct. oral arguments took place yesterday in the ongoing PCSK9* antibody (Ab) patent case. See the attached transcript...

We've reached the final week of Q1. Anything that hasn't read out yet is coming this week! There's over 20 events still set to happen....

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...